Skip to main content

Distinguished Speaker Series | John D. Hulleman, PhD

-
Location
https://ucihealth.zoom.us/j/94483669170?pwd=WUd1clg2aUM1bnpPVHd3MlkwTUN1Zz09
Event Type

Add to Calendar: Outlook | Google | iCal

The Center for Translational Vision Research Distinguished Speaker Series, also known as "Friday Seminars" showcases innovative research across the world. The seminar series has now been expanded to include lectures by experts on topics ranging from Ophthalmology, Genetics, Biochemistry, Neurobiology, Imaging, Computational Sciences to Novel Ophthalmic Treatments.

All talks are hybrid. You can join us in person at

The Susan & Henry Samueli College of Health Sciences 

Sue Gross Auditorium.

You can also join us by zoom. Zoom link and information are on your right and in the calendar links above.

December 6, 2024 |  John D. Hulleman, PhD

GSK3 inhibition remodels the ECM and prevents pathology in an AMD-like retinal dystrophy

 

Learn More About the Distinguished Speaker Series

Featured


John D. Hulleman, PhD,
John D. Hulleman, PhD,
  • Larson Endowed Chair for Macular Degeneration, Associate Professor, Department of Ophthalmology and Visual Neurosciences University of Minnesota, Minneapolis, MN

The overarching goal of research in the Hulleman Lab is to identify and pursue challenging, poorly characterized biological problems with broadly-translatable implications for the treatment of protein misfolding diseases. Specifically, we aim to develop an understanding of the fundamental cellular and molecular mechanisms which underlie age-related and inherited diseases with an emphasis on disorders caused by secreted and extracellular matrix (ECM) proteins.

We employ a multi-disciplinary approach combining chemical biology, cellular/molecular biology, drug discovery, gene therapy, and biochemistry to understand the pathophysiological consequences of altering the cellular protein homeostasis network in the context of aging and disease. Then, using this newly-gained knowledge of disease biology, the Hulleman Lab employs both rational and unbiased drug discovery approaches to identify and validate novel routes of therapeutic intervention.